138 related articles for article (PubMed ID: 20565319)
21. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
23. Controversies in the treatment of wet age-related macular degeneration.
Moreno SF; Paloma JB
Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
[No Abstract] [Full Text] [Related]
24. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
25. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration.
Goverdhan SV; Lochhead J
Br J Ophthalmol; 2008 Feb; 92(2):210-2. PubMed ID: 17965104
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
[TBL] [Abstract][Full Text] [Related]
27. Retinal pigment epithelial tear after intravitreal bevacizumab injection.
Shah CP; Hsu J; Garg SJ; Fischer DH; Kaiser R
Am J Ophthalmol; 2006 Dec; 142(6):1070-2. PubMed ID: 17157598
[TBL] [Abstract][Full Text] [Related]
28. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration.
Lazić R; Gabrić N; Dekaris I; Sarić B; Gavrić M
Coll Antropol; 2007 Jan; 31 Suppl 1():77-81. PubMed ID: 17469757
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases.
Madhusudhana KC; Hannan SR; Williams CP; Goverdhan SV; Rennie C; Lotery AJ; Luff AJ; Newsom RS
Br J Ophthalmol; 2007 Dec; 91(12):1716-7. PubMed ID: 18024821
[No Abstract] [Full Text] [Related]
32. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
[TBL] [Abstract][Full Text] [Related]
33. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
Peter S; Hausmann N; Schuster A; Boehm HF
Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
[No Abstract] [Full Text] [Related]
34. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Rosenfeld PJ; Moshfeghi AA; Puliafito CA
Ophthalmic Surg Lasers Imaging; 2005; 36(4):331-5. PubMed ID: 16156152
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
36. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
[TBL] [Abstract][Full Text] [Related]
37. [Intravitreal bevacizumab for neovascular age-related macular degeneration].
Ladewig MS; Ziemssen F; Jaissle G; Helb HM; Scholl HP; Eter N; Bartz-Schmidt KU; Holz FG
Ophthalmologe; 2006 Jun; 103(6):463-70. PubMed ID: 16763862
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
Jonas JB; Tao Y; Rensch F
Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
